Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Clin Genitourin Cancer. 2017 Apr 26;15(6):e987–e994. doi: 10.1016/j.clgc.2017.04.012

Table 2. Radiographic.

Response to Platinum-based Therapy and Progression Free Survival (PFS)

Patient First Platinum-Based Therapy Line of Therapy Best Responsea PFS (months)
1 Carboplatin/gemcitabine First PR 4.9
2 Carboplatin/gemcitabine First PR 3.9+
3 Carboplatin/gemcitabine First PD 2.0
4 Carboplatin/gemcitabine First SD 1.2
5 Carboplatin/gemcitabine First NE 2.9
6 Carboplatin/gemcitabine First NE 0.1
7 Cisplatin/gemcitabine First PD 2.0
8 Cisplatin/gemcitabine First PD 0.7
9 Cisplatin/gemcitabine First PR 5.4
10 Cisplatin/paclitaxel First PD 1.1
11 Carboplatin/gemcitabine/paclitaxel Second PR 7.0
12 Carboplatin/paclitaxel Second SD 3.1

PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable

a

Response assessed by RECIST v1.1 criteria